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Abst ract  
One of the earliest cellular esponses to growth factors is the rapid induction of primary response genes. One group of such genes was 
originally isolated as tetradecanoyl phorbol acetate (TPA) inducible sequences (TIS genes) from mouse 3T3 cells. Proteins encoded by 
the TIS genes include two transcription factors: TIS8 (also known as egrl/NGFIA/zif268) and TIS1 (also known as NGFIB/nur77/N10). 
We have examined the inducibility of these two genes in a skeletal muscle cell line in response to agents that have been reported to block 
muscle differentiation. We report here that basic fibroblast growth factor (bFGF) induced the expression of both TIS1 and TIS8 in mouse 
C2C12cells. Both genes were also inducible by TPA while forskolin which activates the cAMP-dependent pathway induced TIS1 but not 
TIS8. Down-regulation f protein kinase C (PKC) activity by TPA pretreatment repressed the bFGF induction of TIS1 but had little effect 
on the bFGF-stimulated expression of TIS8. Moreover, while both TPA and bFGF stimulated the hyperphosphorylation of c-RAF and the 
activity of MAP kinase, TPA pretreatment failed to block RAF phosphorylation r the stimulation of MAP kinase activity by bFGF. 
Induction of the two TIS genes in skeletal myoblasts therefore appeared to be dependent to different extents on the activation of protein 
kinase A (PKA), PKC and MAP kinase. 
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1. In t roduct ion  
The differentiation of skeletal muscle cells in vitro is 
under the strict regulation of specific growth factors (re- 
viewed in Ref. [1]). Fibroblast growth factor, for example, 
is a very effective inhibitor of the differentiation process 
[2]. In addition, pharmacological ctivators of both protein 
kinase A and protein kinase C signal transduction path- 
ways have been reported to exert differential effects on 
muscle differentiation [3-10]. The exact mechanisms 
through which growth factors and other agents affect the 
differentiation process have not been elucidated. Available 
evidence suggests, however, that growth factor-induced 
alterations in gene expression may be necessary for the 
differentiation-inhibitory effect [11]. 
Among the earliest changes in gene expression in re- 
sponse to growth factor stimulation is the induction of an 
extensive group of primary response genes that can be 
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induced in the absence of intervening protein synthesis 
(reviewed in Ref. [12]). The spectrum of primary response 
gene expression appears to vary considerably depending 
on the cell type and the inducing ligand. While over-ex- 
pression of some primary response genes (e.g. c-los and 
c-jun) has been shown to repress muscle differentiation 
[13,14], the pattern of primary response gene expression in 
skeletal muscle cells has not been examined in detail. It is 
not clear whether additional primary response genes other 
than c-fos and c-jun can modulate the differentiation 
process. 
We have previously identified a number of primary 
response genes that are rapidly induced by the tumor 
promoter - tetradecanoyl phorbol acetate (TPA) - in the 
mouse embryonic 3T3 cell line [15]. These genes which 
are referred to as TPA- inducible sequences (TIS genes) 
can also be induced in mouse 3T3 cells by serum and by 
peptide growth factors [16]. Some of these TIS genes have 
been identified as serum and nerve growth factor (NGF)- 
inducible genes by other investigators [17-20]. One of the 
TIS genes (T IS1/NGFIB/nur77)  encodes a protein that 
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bears striking sequence similarity to members of the lig- 
and-dependent uclear eceptor superfamily and acts as a 
sequence-specific transcription factor [17,21]. A recent 
report demonstrated that the TIS1/nur77 protein might be 
involved in the transcriptional regulation of a steroid bio- 
synthesis enzyme, 21-hydroxylase [22]. Although no other 
authentic gene targets for TIS1 has been documented, a 
TIS1 DNA binding sequence motif has been found in the 
5' flanking region of the gene encoding the y-subunit of 
the muscle nicotinic acetylcholine r ceptor [23]. Whether 
the TIS1 protein can indeed modulate AChR "y expression 
has not yet been determined. Another TIS gene, 
(TIS8/egrl/zif268) encodes a protein with zinc finger 
structural motifs, metal-dependent sequence-specific DNA 
binding activity; and shares ignificant sequence similarity 
with the Wilms' tumor susceptibility gene product 
[19,20,24,25]. Paradoxically, overexpression f TIS8/egrl  
in cardiac and skeletal muscle cells has been reported to 
transactivate he 5' flanking region of the cardiac myosin 
heavy chain gene [26]. Thus, although TIS1 and TIS8 may 
play some role in the muscle differentiation process, the 
exact nature of their involvement appears to be rather 
complex. 
As an initial step towards investigating the potential 
function of TISI and TIS8 in skeletal muscle cells, we 
report in this paper a comparison of the expression of the 
two TIS genes (TIS1 and TIS8) in the C2C12 skeletal 
muscle cell line in response to bFGF, TPA and forskolin, 
three agents that have been reported to modulate muscle 
differentiation [2,5-7]. We showed that bFGF and TPA 
could induce both TIS1 and TIS8 but that forskolin in- 
duced only TIS1. We showed also that bFGF and TPA 
could stimulate MAP kinase activity in C2C12 cells through 
apparently different signalling pathways, and that the in- 
duction of the two TIS genes by bFGF and TPA was 
dependent to different degrees on the activation of protein 
kinase C and MAP kinase. Induction of the two genes in 
skeletal myoblasts can thus be differentially modulated 
through distinct signal transduction pathways involving 
different kinase cascades. 
2. Material and methods 
2.1. Cell culture 
C2C12 mouse myoblasts (obtained from ATCC) were 
cultured in high glucose Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) on gelatinized plastic tissue culture dishes in 
a 37 ° C, 5% CO 2 humidified incubator. To initiate myo- 
genic differentiation, cells were rinsed twice with Puck's 
saline G, and fed with a differentiation-permissive medium 
consisting of DMEM supplemented with 5% horse serum 
(HS). Recombinant human basic fibroblast growth factor 
(bFGF) used in the experiments was the generous gifts of 
Dr. Stephen Hauschka and Dr. Bradley Olwin. Tetrade- 
canoyl phorbol acetate (TPA) and forskolin were obtained 
from Sigma Chemical Co. (St. Louis, MO). 
2.2. Plasmids 
The derivation and properties of the TIS1 and TIS8 
recombinant cDNA plasmids have been described previ- 
ously [15]. The plasmid pCHOb which recognized a consti- 
tutively expressed mRNA [27] was used as a probe to 
normalize for RNA loading and transferred as described 
earlier [15]. 
2.3. RNA isolation and analysis 
Total RNA was isolated according to the guanidinium 
isothiocyanate-acid-phenol xtraction procedure of Chrom- 
czynski and Sacchi [28] with slight modifications. Two 
sequential phenol extraction steps were performed instead 
of the single extraction step used in the original protocol. 
The second isopropanol precipitation step was eliminated. 
RNA samples were analyzed by electrophoresis on a 1.1% 
agarose gel containing 2.2 M formaldehyde, blotted onto 
nitrocellulose by capillary action and hybridized to ra- 
dioactive cDNA probes generated by random-primed label- 
ing of the respective plasmids according to standard proto- 
cols. Hybridization and washing conditions were as previ- 
ously described [15]. 
2.4. Protein kinase C assay 
In vitro protein kinase C activity was determined by 
measuring 32p incorporation i to a synthetic peptide corre- 
sponding to a fragment of myelin basic protein using the 
protein kinase C assay kit supplied by Life Technology. 
The assay was performed according to the manufacturer's 
suggested protocol. Briefly, cells grown in 100 mm culture 
dishes were harvested into 0.5 ml/dish of extraction buffer 
containing Triton X-100. The extract was clarified by 
centrifugation i  a microfuge and partially purified by 
DE52 chromatography. Aliquots of the eluate were ana- 
lyzed for kinase activity. PKC activity was determined by 
subtracting from the total kinase activity the residual activ- 
ity observed in the absence of lipid and phorbol ester and 
in the presence of a PKC-specific inhibitory peptide. The 
data were normalized to protein concentration f the eluate 
as determined by the BioRad Protein assay. 
2.5. MAP kinase assays 
In vitro kinase assay to determine MAP kinase activity 
was determined essentially as described by Ahn et al 
[29,30]. Briefly, C2C12 cells were grown to near conflu- 
ence and the culture medium was changed to serum-free 
DMEM. 4 h later, the cultures were stimulated with 5 
ng/ml bFGF for various lengths of time as indicated for 
each experiment. The cultures were rinsed once with ice- 
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cold PBS, once with extraction buffer (50 mM fl-glycerol 
phosphate (pH 7.3), 1.5 mM EGTA, 0.1 mM NaaVO 4, 1 
mM dithiothreitol, 10 /zg/ml leupeptin, 10 /~g/ml apro- 
tinin and 1 mM benzamidine) and harvested by scraping 
into extraction buffer. Cells were lysed by brief sonication 
and the lysate was clarified by centrifugation at 13 000 X g 
for 30 min. The supernatant was aliquoted and frozen at 
-70°C until used. The in vitro kinase assay was per- 
formed at 30°C in a reaction mix containing 12.5 /zl of 
cytosol and an equal volume of reaction buffer (50 mM 
/3-glycerol phosphate (pH 7.3), 1.5 mM EGTA, 0.1 mM 
Na3VO4, 200 /~M calmidazolium, 4 /~M PKI, 20 mM 
MgC12, 0.2 mM ATP, ',2.5 /zCi [T-32p]ATP with and 
without 0.5 mg/ml  myelin basic protein). The reaction 
was stopped after 15 min by spotting aliquots on P81 
phophocellulose paper and immersing in 150 mM phos- 
phoric acid. MAP kinase activity was determined as the 
amount of radioactive phosphate incorporated into myelin 
basic protein and was nonualized to the amount of protein 
present in the cell lysate. For the in gel-kinase assay [31], 
aliquots of the cell lysate containing equivalent amount of 
proteins were separated by SDS-PAGE in an acrylamide 
gel impregnated with myelin basic protein. After elec- 
trophoresis, the gel was subjected to sequential denatura- 
tion and renaturation steps, and then incubated in a reac- 
tion mix containing 40 mM Hepes (pH 7.0), 0.5 mM 
EGTA, 10 mM MgC12, 2 /xM PKI, 40 /~M ATP and 25 
/zCi [32p]ATP. The reaction was stopped by transferring 
the gel to 5% TCA and 1% pyrophosphate. After extensive 
washing, the gel was dried and autoradiographed. In some 
experiments, cells were lysed in 1% SDS after stimulation, 
boiled for 10 min and diluted 10-fold into 1 x 
immunoprecipitation buffer (10 mM Tris, 150 mM NaCI, 
1.0% Triton X-100, 0.5% NP40, 1 mM EDTA, 1 mM 
EGTA, 0.2 mM Na3VO 4, 0.2 mM PMSF, 0.2 mM benza- 
midine (pH 7.4)) and incubated overnight with a mono- 
clonal anti-MAPK antibody (Zymed). The immunoprecipi- 
tate was collected with secondary anti-mouse IgG antibody 
and protein A agarose, washed and analyzed by the in-gel 
kinase described above. 
2.6. RAF immunoblot assay 
Equivalent amounts of cell lysate normalized for protein 
content were separated by SDS-PAGE, transferred by elec- 
troblotting to nitrocellulose membrane, incubated with 
1:2000 dilution of anti-RAF antibody (Santa Cruz) and 
analyzed using the ECL chemiluminesence d tection sys- 
tem as described by the manufacturer (Amersham). 
3. Results 
3.1. FGF-induced TIS genes in C2C12 myoblasts 
In addition to being a potent mitogen for many skeletal 
muscle myoblasts, FGF :has also been shown to be an 
CHX(ug/ml)  -- 10 10 10 10 10 10 10 
TPA (/xM) -- 0.01 0.1 1 
FGF  (ng/ml) . . . . . . . .  0.02 0.2 2 -- 
TIS8 
t IS l  
CHOb 
Fig. 1. Dose response ofTIS gene xpression following bFGF and TPA 
treatments. C2C12 cultures were stimulated with the indicated concentra- 
tions of either bFGF or TPA in the presence of 10 /xg cycloheximide 
(CHX). Total RNA was harvested 3 h later, and the expression f various 
TIS genes were determined byNorthern hybridization using the respec- 
tive cDNA probes. The same blot was used sequentially for each of the 
cDNA probes. The plasmid pCHOb which recognizes a constitutively 
expressed mRNA was used for normalization. Each lane contained 10 p~g 
total RNA. Similar esults were obtained in two to three other indepen- 
dent experiments. 
important modulator of the myogenic differentiation pro- 
cess. We and others have shown that one of the earlier 
cellular responses to growth factors and other mitogens is 
the induction of a set of primary response genes (reviewed 
in Ref. [12]). To determine if FGF induces a unique 
combination of primary response genes in muscle cell 
culture, we treated the C2C12 mouse myogenic ells with 
various concentrations of recombinant human basic FGF 
(bFGF) in the presence of 10/xg/ml  cycloheximide (CHX) 
for 3 h, a condition that was known to yield maximal TIS 
gene expression in other biological systems. Total cellular 
RNA was then harvested and analyzed by Northern blot 
analysis. Fig. 1 shows the concentration dependence of the 
induction by TPA and bFGF of two primary response 
genes, TIS1 and TIS8, encoding respectively an orphan 
nuclear eceptor and a zinc finger-type transcription factor. 
Results indicated that both bFGF and TPA induced the two 
TIS genes in a concentration-dependent manner in the 
absence of intervening protein synthesis. Induction of both 
TIS genes by bFGF could be detected after treatment with 
as little as 0.02 ng/ml  of the growth factor. This is 
consistent with the reported high potency of bFGF in 
stimulating other biological responses. In this particular 
experiment, TPA induced TIS1 and TIS8 to a much greater 
extent han bFGF. However, the precise degree of stimula- 
tion in response to the two agents relative to each other 
was quite variable from experiment to experiment depend- 
ing on the cell type [16] and other as yet undefined culture 
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N C T F K ally yielded no detectable hybridization signal even though 
in all cases the differential induction of  TIS1 and TIS8 by 
forskolin was consistently observed. 
TIS8 
TIS1 
CHOb 
Fig. 2. Differential induction of TIS gene expression by bFGF, TPA and 
forskolin. C2C12 cultures were stimulated with either 100 nM TPA (lane 
T), 2 ng/ml bFGF (lane F), 20 /zM forskolin (lane K) in the presence of 
10 p.g/ml CHX. RNA were harvested 3 h later and the level of TIS gene 
expression was analyzed by Northern hybridization. Lane C represents 
RNA from cells treated with CHX alone. Lane N represents RNA from 
cells that were untreated. Each lane contained 10 /xg total RNA. Similar 
results were obtained in at least three separate xperiments. 
T IS1  
CHOb(1)  
T IS8  
CHOb(2)  
A 
TPA 
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C T F K C T F K 
conditions. In the absence of  CHX, induction of  both TIS1 
and TIS8 by bFGF and TPA still occurred, but with a 
much more transient ime course, reaching a peak level 30 
min to 1 h after the addition of the l igands (data not 
shown). Since induction by either bFGF or TPA could be 
detected in the absence of cycloheximide, induction of  
these genes was not dependent on protein synthesis inhibi- 
tion. 
3.2. Agents that activate the cAMP-dependent signal trans- 
duction pathway stimulated TIS1 but not TIS8 
Agents that activate the cAMP dependent pathway have 
been reported to modulate the initiation of  the differentia- 
tion process in skeletal muscle cells [7,15]. To determine if 
the cAMP-dependent  kinase pathway can induce specific 
TIS gene expression in these cells, we treated C2C12 
cultures with the adenylyl cyclase activator forskolin and 
harvested the RNA for Northern blot analysis. As shown in 
Fig. 2, forskolin treatment in the presence of cyclohex- 
imide resulted in substantial induction of  TIS1 whereas no 
induction of  TIS8 could be observed under these super-in- 
ducing conditions. In contrast, bFGF and TPA treatment 
resulted in strong induction of  both TIS1 and TIS8. The 
level of induction for both TIS genes appeared to be lower 
than that shown in Fig. 1 due in large part to the unusually 
prominent level of  'basal '  expression in the untreated (lane 
N) and cycloheximide-treated (lane C) cells. In most other 
experiments, RNA samples form untreated cultures gener- 
B TPA 
CONTROL PRETREATED 
N C T F K N C T F K 
TIS1 
CHOb 
Fig. 3. Effect of TPA pretreatment onTIS gene induction by bFGF, TPA 
and forskolin. (A) Cells were pretreated for 24 h with 200 nM TPA and 
then challenged with either 100 nM TPA (lane T), 2 ng/ml bFGF (lane 
F) or 20 /zM forskolin (lane K). RNA was harvested after 1 h and 
analyzed by Northern hybridization against he various eDNA probes 
indicated. Parallel cultures without TPA pretreatment were stimulated in a 
similar manner. No CHX was used in this experiment. Lane C represents 
control cultures that received no additional stimulation. Each lane con- 
tained 10 /zg total RNA. Two separate nitrocellulose blots containing 
replicate RNA samples were used in the experiment. Results of the 
hybridization of each of the two blots to the control pCHOb plasmid are 
shown, pCHOb(1) corresponds to the blot used for TIS1. pCHOb(2) 
corresponds to the blot used for TIS8. Similar results were obtained in at 
least two independent experiments. (B) Induction of TIS1 mRNA by 
bFGF following pretreatment with lower concentrations of TPA. Cells 
were pretreated with 100 nM TPA for 24 h and then stimulated for 1 h 
with the indicated agents in the presence of 10 /zg/ml CHX: 100 nM 
TPA (lane T), 2 ng/ml bFGF (lane F), or 20 /~M forskolin (lane K). 
Lane C represents a culture treated with CHX alone. Lane N represents a 
culture that received no additional treatment. Parallel cultures without 
prior TPA pretreatment (control) were stimulated in similar manner. 
Similar results were obtained in at least three other experiments. 
3.3. Induction of TIS genes by bFGF occurred through 
both protein kinase C &,.pendent and independent path- 
ways 
Stimulation by FGF has been linked to the activation of 
phospholipase C and the subsequent activation of the 
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protein kinase C (PKC)-dependent signal transduction 
pathway [32,33]. In order to see if bFGF induction of TIS 
genes in C2C12 cells might be mediated through PKC 
activation, we pretreated cells for 24 h with TPA to down 
regulate the protein kinase C activity, then stimulated the 
cells with either bFGF, TPA or forskolin and examined the 
level of TIS gene expression. In contrast o short- term 
treatments hat lead to rapid stimulation of PKC, prolonged 
TPA treatment has been shown to result in the proteolytic 
degradation of PKC and the loss of enzyme activity [34,35]. 
As shown in Fig. 3a, myoblasts pretreated with 200 nM 
TPA lost the ability to respond to a subsequent TPA 
challenge but the induction of TIS8 by bFGF was essen- 
tially unimpaired. Interestingly, the TPA pretreatment sig- 
nificantly reduced the level of TIS1 expression in response 
to bFGF without affecting the response of TIS1 to forskolin. 
To further examine the role of PKC in the bFGF induction 
of TIS1, we repeated the analysis by pretreating with a 
lower concentration of TPA and examined the induction in 
the presence of cycloheximide so as to maximize the 
induction response. As shown in Fig. 3b, pretreatment with 
a lower concentration of TPA (100 nM) substantially 
reduced but did not completely abolish the ability of bFGF 
to induce TIS1 even though the induction of TIS1 by TPA 
was still effectively repressed. These results suggest hat 
bFGF induction of TIS1 might be mediated through both 
PKC-dependent and independent pathways. Data shown in 
Fig. 3b also appear to indicate that TPA pretreatment 
caused reduced levels of 'basal '  TIS1 expression in the 
presence of cycloheximide. For reasons that are not en- 
tirely understood, this effect appeared to be variable, and 
occurred to different extents in three-fourths of the TPA 
pretreatment experiments. The differential effect of TPA 
pretreatment on the bFGF inducibility of TIS1 and TIS8 
was, however, consistently observed in all experiments. 
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Fig. 4. Activation of c-RAF and MAPK by bFGF in C2C12 cells. (A) 
Near confluent C2C12 cultures were exposed to serum free-medium for 4 
h and then stimulated with 5 ng/ml bFGF for the indicated times. MAPK 
activity was assayed as described in Section 2 and normalized to the 
protein content of each sample. The time course of MAPK activation was 
calculated as -fold stimulation over the untreated controls. Each point 
represents data from duplicate dishes. The experiment was performed 
three times with similar esults. (B) Total cell lysates and immunoprecip- 
itates from control C2C12 cells and C2C12 cells stimulated for 5 min 
with 5 ng/ml bFGF were fractionated by SDSPAGE in a gel impreg- 
nated with myelin basic protein and the kinase activity was analyzed by 
the in-gel kinase as described in Section 2. Lanes 1 and 2 represent 
immunoprecipitates withan irrelevant monoclonal ntibody MF20, con- 
trol (lane 1), bFGF stimulated (lane 2); lanes 3 and 4 represent immuno- 
precipitates with the anti-MAP kinase (aMAPK) antibody, control (CON), 
bFGF-treated (FGF); lanes 5 and 6 represent samples of total cell lysate, 
control (CON), bFGF-stimulated (FGF). (C) C2C12 cells stimulated with 
bFGF (5 ng/ml) for the indicated times were lysed in sample buffer. The 
samples were fractionated by SDS-PAGE on an 8% acrylamide gel, 
transferred tonitrocellulose and incubated with anti-RAF antibody (Santa 
Cruz), and visualized by enhanced chemiluminesence as described in 
Section 2. 
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Table 1 
Effect of TPA pretreatment on in vitro PKC activity 
PKC activity 
pmol /min/mg (% Control) b 
protein a 
Experiment 1 
No pretreatment 0.365 100 
50 nM TPA, 24 h pretreatment 0.119 32.6 
100 nM TPA, 24 h pretreatment 0.047 12.9 
200 nM TPA, 24 h pretreatment 0.030 8.2 
400 nM TPA, 24 h pretreatment 0.026 7.1 
Experiment 2 
No pretreatment 0.867 100 
100 nM TPA, 14 h pretreatment 0.154 17.8 
100 nM TPA, 24 h pretreatment 0.175 20.2 
100 nM TPA, 32 h pretreatment 0.20 23.1 
a PKC activity was determined as described in Section 2. Each value 
represents the average of duplicate measurement with less than 5% 
maximal deviations from the mean. 
b PKC activity level from each sample was normalized to the activity 
observed in the no treatment control sample. 
To confirm that TPA pretreatment had indeed down- 
regulated the PKC activity in the C2C12 cells, we ana- 
lyzed the effect of TPA pretreatment on the level of in 
vitro PKC activity. As shown in Table 1, pretreatment with 
100 nM TPA for 24 h reduced the in vitro PKC activity to 
13-20% of the control evel. Increasing the concentration 
of TPA used in the pretreatment caused only a small 
further decrease in the PKC activity, while increasing the 
length of pretreatment did not result in any further decline 
in activity. 
3.4. FGF treatment of C2C12 cells resulted in hyperphos- 
phorylation of the RAF-1 protein and increased the activ- 
ity of MAP kinases 
In addition to activation of the PKC pathway, stimula- 
tion with many growth factors is known to increase the 
activity of the mitogen activated protein kinases (MAPK) 
through a c-RAS- and c-RAF-dependent signal transduc- 
tion pathway. To see if MAPK might be activated by 
bFGF in C2C12 cells, we stimulated C2C12 cells with 5 
ng/ml bFGF for various times and the cell lysate was 
analyzed for MAPK activity using myelin basic protein as 
the substrate under conditions that should inhibit other 
known major kinases. As shown in Fig. 4a, bFGF stimula- 
tion resulted in a small (1.5-2-fold) but consistent increase 
in myelin basic protein kinase activity that peaked at 2-5 
min of bFGF treatment. This increase in activity was 
followed by a decline to a lower level by 10 min and 
remained at that level up to 30 min after the addition of 
bFGF. This bFGF-activated kinase migrated on SDS-PAGE 
with an apparent molecular mass of about 42 kDa as 
revealed by an in-gel kinase assay (Fig. 4b). In addition, 
antibody directed against he p44 and p42 MAPK (Zymed) 
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.~ 2.0 
-o 
f 
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.~  0 .5  
o_ 
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07 .~  
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C 
NA FGF TPA NA FGF TPA 
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Fig. 5. TPA pretreatment did not affect bFGF stimulation of MAPK 
activity or c-RAF hyperphosphorylation. (A) C2C12 cells were pretreated 
for 24 h with 100 nM TPA or left untreated then stimulated with 5 ng/ml 
bFGF or 100 nM TPA for 5 min. MAPK activity was assayed as 
described in Fig. 4A, normalized to protein content and expressed as -fold 
stimulation over control samples without bFGF treatment. The error bars 
indicate standard error of the mean from three independent experiments 
with duplicate samples. (B) Cultures were pretreated as described in (A) 
except hat 200 nM TPA was used for the pretreatment. The remainder of 
the experiment was carried out as described in (A). (C) Cultures were 
treated as described in (A). The cell lysate was then fractionated by 
SDS-PAGE and analyzed by immunoblot with anti-RAF antibody using 
the ECL detection system as described in Section 2. 
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precipitated a protein kinase with molecular mass of ap- 
prox. 42-44 kDa that was activated in response to bFGF 
stimulation (Fig. 4b). Activation of the myelin basic pro- 
tein kinase activity was also correlated with increases in 
slower migrating forms of c-RAF protein as revealed by 
immunoblot of C2C12 cell extracts following bFGF treat- 
ment (Fig. 4c). Consistent 'with its apparent potency in TIS 
gene induction, lower concentrations of bFGF (down to 1 
ng/ml) were able to stimulate a substantial increase in the 
myelin basic protein kinase activity (data not shown). 
Taken together, the results, suggest hat bFGF might acti- 
vate MAPK in C2C12 cells through a RAF-dependent 
pathway as previously determined for other growth factors. 
3.5. Activation of the c-RAF/MAPK pathway by bFGF 
correlated with the induction of TIS8 but not TIS1 
MAP kinase activation iis believed to be involved in the 
induction of gene expression through either direct or indi- 
rect phosphorylation f wtrious transcription factors [36]. 
To determine if activation of MAP kinase by bFGF was 
sufficient to account for the induction of TIS genes by 
bFGF, we pretreated cells with TPA under conditions (100 
nM for 24 h) known to interfere with bFGF induction of 
TIS1 expression (see Fig. 3) and determined if the bFGF 
activation of MAPK was affected under such conditions. 
As shown in Fig. 5a, pretreatment with TPA blocked 
subsequent s imulation of myelin basic protein kinase ac- 
tivity by TPA but did not affect the bFGF-induced activa- 
tion of the protein kinase, even though under similar 
conditions the induction of TIS1 by bFGF was substan- 
tially reduced (see Fig. 3b). Pretreatment with a higher 
concentration of TPA (200 nM) which almost completely 
abolished the TIS1 inducibility by bFGF (see Fig. 3a) 
likewise had no effect on the ability of bFGF to stimulate 
the MAP kinase activity (Fig. 5b). In addition, PKC 
down-regulation did not reduce the apparent hyperphos- 
phorylation of c-RAF protein in response to bFGF (Fig. 
5c), consistent with previous reports that RAF activation 
by growth factor occurs through a RAS-dependent path- 
way [37-40]. The results thus demonstrated that bFGF 
could activate MAPK through a PKC-independent path- 
way in C2C12 cells and that activation of MAPK per se 
was not sufficient o account for full induction of TIS1 by 
bFGF. 
4. Discussion 
Exposure of cells to different ypes of ligands induces 
distinct but overlapping sets of primary response genes. 
The precise pattern of primary response gene expression 
may contribute to distinct functional consequences specific 
for individual stimuli. In this report, we describe, for the 
first time, the induction of two primary response genes 
(TIS1 and TIS8) in a skeletal muscle cell line, by agents 
that are known to affect the differentiation process (see 
below) and activate specific signal transduction pathways. 
We showed that stimulation by bFGF and TPA induced 
both TIS1 and TIS8 (Fig. 1), while forskolin, which 
activates the PKA-dependent pathway, induced only TIS1 
(Fig. 2). Similar results were observed with other muscle 
cell lines such as BC3H1 [5] and a myogenic ell line 
derived from 5-azacytidine-treated 10T1/2 fibroblasts [41], 
suggesting that induced expression of the two TIS genes 
could be a general property of skeletal muscle cells (un- 
published observations). 
Although stimulation of the TIS genes was consistently 
observed, the basal level of TIS gene expression and the 
relative level of the induction by bFGF and TPA were 
somewhat more variable. The exact explanation for this 
variability is not known, but could be related to the growth 
and culture condition of the cells. The basal level of TIS1 
expression, for example, appeared to be dependent on the 
state of cell proliferation and differentiation (unpublished 
observation). In addition, chronic stimulation of tyrosine 
kinase-dependent signalling pathways has been shown to 
depress subsequent inducibility of various primary re- 
sponse genes including TIS1 and TIS8 [42]. 
Whether the induction of TIS1 and TIS8, both encoding 
sequence-specific transcription factors, might be related to 
the muscle differentiation process is not clear. Previous 
studies have demonstrated bFGF to be a potent inhibitor of 
skeletal muscle differentiation [2,43,44]. Similarly, the PKC 
activator, TPA, has been shown to inhibit muscle differen- 
tiation and reverse the differentiated phenotype when added 
to differentiated cells in culture [3,4,10]; and the PKC- 
mediated phosphorylation f the muscle-specific transcrip- 
tion factor myogenin has been correlated with the loss of 
its transactivating ability [45]. Agents that raise intra- 
cellular cAMP level have likewise been reported to inter- 
fere with the myogenic differentiation process [5-9]. Un- 
der the cell culture conditions used in our laboratory, 
however, bFGF was a much stronger inhibitor of myogenic 
differentiation than either TPA or FK (unpublished obser- 
vations). Yet, all three agents induced TIS1 to a similar 
degree (Fig. 2). Likewise, the lack of TIS8 induction by 
forskolin could not completely account for the inability of 
forskolin to inhibit muscle differentiation, since TPA and 
bFGF induced TIS8 to a similar extent but differ substan- 
tially in their differentiation i hibitory effect. Our data 
therefore did not support a simple correlation between 
induction of either TIS gene with the inhibition of myoge- 
nesis, although they did not rule out the possibility that 
expression of these genes may contribute to the overall 
regulatory process. 
Other evidence suggests that, in addition to their poten- 
tial involvement in modulating the initiation of the myo- 
genic process, the expression of the two TIS genes may be 
relevant o physiological processes in the differentiated 
muscle tissues. Although TIS1 and TIS8 were originally 
identified as mitogen-inducible g nes, many of the TIS 
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genes including TIS1 and TIS8 can be induced by a 
variety of non-mitogenic stimuli in other cell types ([46], 
reviewed in Ref. [12]). It seems plausible, therefore, that 
TIS1 and TIS8 would also be induced by neuroendocrine 
signals in the differentiated muscle fibers. A recent study, 
for example, showed that both TIS1 and TIS8 were indeed 
expressed at low level in skeletal muscle tissues in vivo 
and that the expression of both genes can be enhanced by 
cycloheximide injection [47]. The findings that overexpres- 
sion TIS8 protein can activate the cardiac myosin heavy 
chain gene [26], and that a TIS1 binding motif is located 
upstream of the gene encoding the acetylcholine r ceptor 
3,-subunit [23], thus raise the possibility that TIS1 and 
TIS8 expression could play some role in mediating the 
transcriptional responses of differentiated muscle fibers to 
physiological changes in the tissue environment. The pre- 
cise biological effects of TIS1 and TIS8 expression could 
be different under different biological contexts, depending 
perhaps on posttanslational modifications or the expression 
levels of other primary response genes. 
Like many growth factors, bFGF interacts with cell 
surface receptors exhibiting a tyrosine kinase activity. 
Recent studies have shown that the activated FGF receptor 
can associate with and stimulate phospholipase C'y (PLC3,) 
to produce inositol phosphate and diacylglycerol, but that 
the activation of PLC is not necessary for mitogenesis 
[32,33]. Whether induction of gene expression by FGF is 
dependent on PLC activation cannot be deduced from 
these studies. Moreover, while other growth factors ap- 
peared to stimulate the tyrosine phosphorylation f a p91 
transcription factor, no p91 phosphorylation or nuclear 
translocation was observed in response to FGF [48]. How 
FGF stimulation results in specific gene activation thus 
remains largely unknown. 
Results from this study demonstrated that bFGF might 
induce different growth factor-inducible primary response 
genes through distinct signal transduction pathways. Even 
though both bFGF and TPA could stimulate TIS gene 
expression in control C2C12 cells, only bFGF could in- 
duce TIS8 expression in cells that have been pretreated 
with TPA to down-regulate PKC (Fig. 3a). Although resid- 
ual PKC activity was detected by an in vitro kinase assay 
(Table 1), the level of activity was insufficient to mount a 
significant gene induction response to PKC activating ago- 
nists such as TPA (Fig. 3a). Induction of TIS8 by bFGF 
thus appeared to occur in a PKC-independent manner. In 
contrast, the induction of TIS1 by bFGF was more sensi- 
tive to TPA pretreatment (Fig. 3a). Since the induction of 
TIS1 by forskolin was not diminished in the TPA-pre- 
treated cell, the reduced inducibility by bFGF did not 
result from nonspecific effects of the TPA pretreatment. 
Induction of TIS1 by bFGF thus appeared to be mediated 
at least in part through the PKC pathway. However, since 
pretreatment with a lower concentration of TPA sup- 
pressed the TPA inducibility of TIS1 to a greater extent 
than the inducibility by bFGF (Fig. 3b), the PKC-depen- 
dent pathway might be only partially responsible for the 
bFGF induction of TIS1. 
It is interesting to note that a significant portion of the 
total PKC activity present was relatively resistant to TPA 
mediated own-regulation. The residual PKC activity might 
correspond to the down-regulation resistant isozymes that 
have been previously reported in other systems [49]. In this 
regard, a recent report indicates that a major PKC species 
present in skeletal muscle appeared to be a novel isozyme 
(n-PKC 0) [50]. The sensitivity of this isozyme to TPA-in- 
duced down-regulation has not been determined. The rela- 
tive abundance of this isozyme in proliferating myoblasts 
prior to muscle differentiation is also not known. 
To further dissect the FGF-activated signalling path- 
way, we showed that treatment of C2C12 cells with either 
bFGF or TPA resulted in the hyperphosphorylation of the 
c-RAF protein and the activation of MAP kinase (Fig. 4). 
While the activation of both RAF and MAPK occurred 
very rapidly following bFGF treatment, the decline in 
MAPK activity appeared to precede the dephosphorylation 
of RAF. The resulting biphasic time course of MAPK 
activation implies the existence of a feedback mechanism 
to repress MAPK activity prior to the complete inactiva- 
tion of RAF. Recently, a MAPK-selective phosphatase that 
is induced in response to agents that activate MAPK has 
been identified [51]. The balance between the continuing 
activation signal from RAF and the activity of this phos- 
phatase could be instrumental in determining the degree 
and duration of the delayed prolonged phase of MAPK 
activation. 
Consistent with previous observations that other growth 
factors can activate MAP kinase through c-RAS activation 
[37-40,52,53], the hyperphosphorylation of RAF and acti- 
vation of the myelin basic protein kinase activity by bFGF 
in C2C12 cells was found to occur in a protein kinase 
C-independent manner (Fig. 5). Moreover, since the 
RAF/MAPK pathway was activated to the normal extent 
by bFGF under conditions of PKC down-regulation where 
TIS1 induction by bFGF was drastically reduced (Fig. 3), 
activation of MAP kinase through the RAS/RAF pathway 
by bFGF cannot account for full induction of TIS1. In- 
stead, the induction of TIS1 by bFGF may rely, at least in 
part, on some PKC activated pathways that are indepen- 
dent of MAP kinase. In this regard, we have shown 
previously that TPA treatment of a mouse 3T3 cell variant 
(TNR9) that is defective in the activation of p42 MAP 
kinase in response to TPA [54] resulted in near normal 
induction of most TIS genes [16]. The finding indicates 
that activation of the p42 MAP kinase was not essential for 
PKC-mediated TIS gene induction in the 3T3-TNR9 vari- 
ant, although whether the PKC-dependent induction of 
TIS1 in C2C12 cells could likewise occur in the absence 
of MAP kinase activation would have to await more direct 
demonstration. In contrast o the results with TIS1, our 
data is consistent with the possibility that MAP kinase 
activation may be responsible for the PKC-independent 
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Fig. 6. A schematic representation of the signal transduction pathways involved in the induction of TIS1 and TIS8 in C2C12 cells by bFGF, TPA and 
forskolin. Solid thick arrows indicate the major pathways ofTIS gene induction while the broken arrow represents a potential weak auxiliary pathway. 
induction of TIS8 by bFGF, although the validity of this 
inference also remains to be proven. Nevertheless, results 
form this study suggest that the bFGF-mediated signals 
diverge early to activate different primary response genes 
through distinct signal tra.nsduction pathways such that 
distinct protein kinase cascades may be involved in the 
regulation of different TIS genes. A diagrammatic llustra- 
tion of the putative signal transduction pathways involved 
in the induction of TIS1 and TIS8 is shown in Fig. 6. 
In summary, we have demonstrated that the expression 
of two primary response genes with well-characterized and 
potentially important biological functions were differen- 
tially induced in a skeletal muscle cell line by agents 
including bFGF that actiwtte different signal transduction 
pathways. The finding underscored the complexity of 
bFGF-induced responses in skeletal muscle cells in addi- 
tion to the previously reported posttranslational modifica- 
tion of myogenic regulatory factors [45] and the induction 
of protooncogenes [13,14]. Although induction of TIS1 
and TIS8 may not be directly related to the differentiation 
process, expression of these genes in response to bFGF 
and other stimuli should affect the long-term physiological 
state of the cells by modulating the expression of their 
respective subsets of secondary response genes. We have 
shown also that bFGF stimulation of C2C12 myoblasts 
resulted in the apparent activation of c-RAF and MAP 
kinase in a PKC-independent manner and that bFGF regu- 
lated the expression of the two primary response genes, 
TIS1 and TIS8, through distinct signal transduction mecha- 
nisms dependent to different degrees on PKC and MAPK. 
The detailed molecular mechanisms regulating the expres- 
sion of these genes and how the induction of these and 
other primary response genes could together orchestrate 
the biological responses in the skeletal muscle cell system 
are important questions that await further exploration. 
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